Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,591,321 papers from all fields of science
Search
Sign In
Create Free Account
lexatumumab
A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
IMC 1121B
Inhibition of Cell Proliferation
Positive Regulation of Apoptosis
TNFRSF10B protein, human
Expand
Narrower (1)
LY3009806
Broader (1)
Monoclonal Antibodies
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.
M. Merchant
,
J. Geller
,
+11 authors
C. Mackall
Journal of clinical oncology : official journal…
2012
Corpus ID: 207033228
PURPOSE Lexatumumab is an agonistic, fully human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing…
Expand
2012
2012
RIP1 Protein-dependent Assembly of a Cytosolic Cell Death Complex Is Required for Inhibitor of Apoptosis (IAP) Inhibitor-mediated Sensitization to Lexatumumab-induced Apoptosis*
F. Basit
,
R. Humphreys
,
S. Fulda
The Journal of Biological Chemistry
2012
Corpus ID: 46706774
Background: Rhabdomyosarcomas (RMS) are often resistant to TRAIL-induced apoptosis. Results: IAP inhibitors prime RMS cells to…
Expand
Highly Cited
2010
Highly Cited
2010
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.
H. Wakelee
,
A. Patnaik
,
+6 authors
A. Tolcher
Annals of oncology : official journal of the…
2010
Corpus ID: 23436414
BACKGROUND Lexatumumab (HGS-ETR2) is a fully human agonistic mAb to the tumor necrosis factor-related apoptosis-inducing ligand…
Expand
Highly Cited
2010
Highly Cited
2010
TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5
J. Lemke
,
A. Noack
,
+7 authors
A. Trauzold
Journal of Molecular Medicine
2010
Corpus ID: 8593437
Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) and agonistic anti-DR4/TRAIL-R1 and anti-DR5/TRAIL-R2 antibodies…
Expand
Highly Cited
2009
Highly Cited
2009
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
T. Luster
,
J. Carrell
,
K. McCormick
,
David Sun
,
R. Humphreys
Molecular Cancer Therapeutics
2009
Corpus ID: 11989124
Mapatumumab and lexatumumab are fully human monoclonal antibodies that bind and activate human tumor necrosis factor-related…
Expand
Highly Cited
2007
Highly Cited
2007
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
R. Plummer
,
G. Attard
,
+11 authors
J. D. de Bono
Clinical Cancer Research
2007
Corpus ID: 5873461
Purpose: To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of…
Expand
Highly Cited
2007
Highly Cited
2007
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
L. Belyanskaya
,
T. Marti
,
S. Hopkins-Donaldson
,
S. Kurtz
,
E. Felley-Bosco
,
R. Stahel
Molecular Cancer
2007
Corpus ID: 13486895
BackgroundThe incidence of malignant pleural mesothelioma (MPM) is associated with exposure to asbestos, and projections suggest…
Expand
2007
2007
A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
E. Petrucci
,
L. Pasquini
,
+11 authors
U. Testa
Gynecologic oncology
2007
Corpus ID: 32455742
Highly Cited
2007
Highly Cited
2007
Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
S. Nawrocki
,
J. Carew
,
L. Douglas
,
J. Cleveland
,
R. Humphreys
,
J. Houghton
Cancer research
2007
Corpus ID: 8266952
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in malignant cells by binding to…
Expand
Highly Cited
2007
Highly Cited
2007
A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI
B. Sikic
,
H. Wakelee
,
+7 authors
H. Burris
2007
Corpus ID: 75339520
14006 Background: Lexatumumab (HGS-ETR2) is a fully-human agonistic monoclonal antibody that targets and activates the Tumor…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE